Directorate Change

GlaxoSmithKline PLC
26 October 2004


Issued -  Tuesday 26 October 2004, London




                              GlaxoSmithKline plc
                   Appointment Of New Chief Financial Officer


GSK announces that Julian Heslop, currently Senior Vice President, Operations
Controller at GSK will succeed John Coombe as Chief Financial Officer of
GlaxoSmithKline plc and will join the Board on John Coombe's retirement on 31st
March 2005.

Sir Christopher Hogg, the Chairman of GSK, said "The Board warmly welcomes
Julian Heslop as John Coombe's successor when John retires next year.  In the
months until John's retirement, the Board will be working closely with both him
and Julian to ensure a smooth transition."

Commenting on his appointment Dr. JP Garnier, the Chief Executive of GSK, said 
"I am delighted to welcome Julian as the next Chief Financial Officer of
GlaxoSmithKline.  Julian is a superb executive and with his strong financial and
leadership ability he will make a great contribution to GSK.  I am particularly
pleased that this appointment demonstrates the depth of management talent in the
company."

Biographical details of Julian are given below.


S M Bicknell
Company Secretary
26th October 2004





Biographical Details

Age 50.  Julian joined Glaxo Wellcome plc as Financial Controller on 1st April
1998.   Following completion of the merger of Glaxo Wellcome and SmithKline
Beecham in January 2001 he was appointed Senior Vice President, Operations
Controller at GlaxoSmithKline plc.  Prior to joining Glaxo Wellcome Julian held
senior finance roles at Grand Metropolitan PLC.

Julian is a Fellow of the Institute of Chartered Accountants in England and
Wales.



Note

The appointment of Julian Heslop as Executive Director and Chief Financial
Officer was made by the Board on the recommendation of the Nominations Committee
which is chaired by Sir Christopher Hogg and comprises two other independent
Non-Executive Directors.



Enquiries:

UK Media enquiries:                     Philip Thomson          [phone]
                                        David Mawdsley          [phone]
                                        Chris Hunter-Ward       [phone]

US Media enquiries:                     Nancy Pekarek           [phone]
                                        Mary Anne Rhyne         [phone]
                                        Patricia Seif           (215)  751 7709

European Analyst/Investor enquiries:    Duncan Learmouth        [phone]
                                        Anita Kidgell           [phone]

US Analyst/ Investor enquiries:         Frank Murdolo           [phone]
                                        Tom Curry               [phone]





                      This information is provided by RNS
            The company news service from the London Stock Exchange